916421-36-8

Basic information

• Product Name: TERT-BUTYL 3-(4-AMINOPHENYL)AZETIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 3-(4-AMINOPHENYL)AZETIDINE-1-CARBOXYLATE
• CAS NO: 916421-36-8
• Molecular Formula: C₁₄H₂₀N₂O₂
• Molecular Weight: 248.3208
• Mol File: 916421-36-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: TERT-BUTYL 3-(4-AMINOPHENYL)AZETIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 3-(4-AMINOPHENYL)AZETIDINE-1-CARBOXYLATE(916421-36-8)
• EPA Substance Registry System: TERT-BUTYL 3-(4-AMINOPHENYL)AZETIDINE-1-CARBOXYLATE(916421-36-8)

Safety Data

• Hazardous Substances Data: 916421-36-8(Hazardous Substances Data)

Usage

General Description

Tert-butyl 3-(4-aminophenyl)azetidine-1-carboxylate is a chemical compound with a molecular formula C13H20N2O2. It is a derivative of azetidine, a heterocyclic organic compound. tert-butyl 3-(4-aminophenyl)azetidine-1-carboxylate is a tert-butyl ester of 3-(4-aminophenyl)azetidine-1-carboxylic acid, and it has a tert-butyl group attached to the azetidine ring. Azetidines are known for their potential pharmaceutical activity, and the presence of an amino group and a carboxylate group in this molecule suggests that it may have biological and medicinal applications. The specific properties and potential uses of tert-butyl 3-(4-aminophenyl)azetidine-1-carboxylate would depend on further research and testing.

Upstream product

• 883901-62-0 tert-butyl 3-(4-nitrophenyl)azetidine-1-carboxylate 
• 254454-54-1 tert-butyl-3-iodoazetidine-1-carboxylate 
• 636-98-6 p-nitrobenzene iodide 
• 7003-80-7 p-aminophenyltriethoxysilane 

Downstream Products

• 1566543-77-8 tert-butyl 3-(4-((4-((2-(1-(methoxycarbonyl)cyclopropyl)phenyl)ethynyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)azetidine-1-carboxylate 
• 1566543-79-0 tert-butyl 3-(4-((4-(2-(1-carbamoylcyclopropyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)azetidine-1-carboxylate 
• 1566542-79-7 1-(2-(2-(2-((4-(azetidin-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)cyclopropanecarboxamide 
• 1566543-78-9 tert-butyl 3-(4-((4-(2-(1-(methoxycarbonyl)cyclopropyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)azetidine-1-carboxylate 
• 1566543-57-4 tert-butyl 3-(4-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)azetidi ne-1-carboxylate 
• 1566584-89-1 tert-butyl 3-(4-((4-((2-(2-methoxy-2-oxoethyl)phenyl)ethynyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)azetidine-1-carboxylate 
• 1566584-90-4 tert-butyl 3-(4-((4-(2-(2-methoxy-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)azetidine-1-carboxylate 
• 1566584-91-5 2-(2-(2-(2-((4-(1-(tert-butoxycarbonyl)azetidine-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetic acid 
• 1566584-92-6 tert-butyl 3-(4-((4-(2-(2-amino-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)azetidine-1-carboxylate 
• 1566584-02-8 2-(2-(2-(2-((4-(azetidine-3-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide 
• 1566585-32-7 tert-butyl 3-(4-((4-(2-(2-amino-2-oxoethyl)phenethyl)-5-methylpyrimidin-2-yl)amino)phenyl)azetidine-1-carboxylate 
• 1566584-14-2 2-(2-(2-(2-((4-(azetidin-3-yl)phenyl)amino)-5-methylpyrimidin-4-yl)ethyl)phenyl)acetamide 

Relevant articles and documents

Palladium-catalyzed hiyama cross-couplings of arylsilanes with 3-Iodoazetidine: Synthesis of 3-arylazetidines

The first palladium-catalyzed Hiyama cross-coupling reactions of arylsilanes with 3-iodoazetidine were described. The protocol provides a convenient access to a variety of useful 3-arylazetidines which are of great interest in pharmaceutical laboratories in moderate to good yields (30%-88%). In addition, this strategy has the advantage of easy operation and mild reaction conditions.

VEGFR3 INHIBITORS

This invention relates to compounds of the formula (I). The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphanglogenesis.